Interactive modules by Olga Goodman, MD.Copyright protected · Read termsClose terms

All RheumaView™ interactive modules, quizzes and educational cases are original works developed by Olga Goodman, MD.

Without the author’s prior written permission, you may not copy or republish these modules or their components; extract, reuse or modify their original software code (“engines”); or use that code to build your own modules, quizzes or other products.

You may not claim these works as your own or remove or replace the author’s name or copyright notices. When quoting material, credit Olga Goodman, MD, identify the source and include a direct link to the original.

Free or public access is provided for learning and does not grant permission to copy, adapt or redistribute the materials. Unauthorized use of protected material may constitute copyright infringement. Exceptions and limitations provided by applicable law remain unaffected.

Sharing direct links to the modules is welcome.

© 2026 Olga Goodman, MD. All rights reserved.

Reactive arthritis · Patient perspective · Chapter 08

When Arthritis Does Not Settle

A longer course calls for a fresh assessment and a treatment plan that matches the remaining inflammation.

Olga Goodman, MD · RheumaView · Evidence checked 2 October 2026 · 3 min read

On this page
  1. First ask what is still causing symptoms
  2. What is a DMARD?
  3. Starting treatment includes a safety plan
  4. What about biologic or targeted medicines?
  5. Measure benefit in your own life
  6. Longer treatment is not a prediction of lifelong disease

First ask what is still causing symptoms

Pain can come from active joint inflammation, an inflamed tendon attachment, weakness, mechanical strain or a combination. Your clinician should re-examine the affected areas before simply adding a stronger medicine.

The diagnosis may also need another look. Psoriasis, persistent bowel symptoms, repeated eye inflammation or a continuing back-pain pattern can reveal a broader form of SpA. A revised diagnosis can make treatment more accurate; it does not mean that your earlier symptoms were not real. [1]

What is a DMARD?

A disease-modifying antirheumatic drug, or DMARD, is used to control continuing inflammatory disease. It is different from a medicine taken only for immediate pain relief. It may take time to work, so a short-term symptom plan and a review date are important.

Sulfasalazine and methotrexate are among the medicines a rheumatologist may consider for persistent peripheral arthritis. The evidence is not equally strong for every drug. Sulfasalazine has been studied directly in reactive arthritis, with mixed results; methotrexate use relies more on experience and evidence from related inflammatory conditions. [2] [3]

Starting treatment includes a safety plan

Before a DMARD, the clinician reviews blood tests, kidney and liver health, other medicines, infection risks and pregnancy plans as appropriate to the drug. Monitoring continues after treatment begins.

Ask for clear written instructions. If methotrexate is prescribed, it is normally taken once a week, not daily; the folate schedule should also be explained. Methotrexate is not suitable during pregnancy, so reproductive planning must be discussed before starting it. Do not assume that rules for pregnancy, breastfeeding and a partner's treatment are identical. [4]

What about biologic or targeted medicines?

Biologic medicines are used to treat reactive arthritis. TNF inhibitors, such as adalimumab or etanercept, can help when active inflammation is severe or persists despite usual treatment. Their use is not confined to other forms of SpA. [7]

Studies in people with reactive arthritis have reported improvement with TNF inhibitors. The evidence is mainly observational: fewer large trials means greater uncertainty, not evidence that these medicines do not work. The rheumatologist selects treatment according to the inflammation, previous response and safety checks. [8] [9]

New reports do not automatically establish a standard treatment. For example, a short observational study of the targeted synthetic medicine tofacitinib is informative but cannot settle long-term safety or show that it should be preferred for everyone. The clinician should explain what evidence applies directly to your condition, what is borrowed from related diseases and which risks matter for you. [5]

Measure benefit in your own life

Agree on signs of improvement: less visible swelling, better walking, fewer nighttime awakenings or less need for steroids. Blood tests may contribute, but they are not the entire assessment.

Also agree on when the medicine will be reviewed and what happens if it is ineffective or poorly tolerated. Waiting for a DMARD to work should not mean being left without contact while symptoms deteriorate. Keep a current medication list and tell the team about new infections or other important changes.

Longer treatment is not a prediction of lifelong disease

Some people need treatment for longer than they first expected. The need for a DMARD now does not determine exactly how long you will need it. Decisions about reducing treatment depend on sustained improvement, the particular medicine and the evolving diagnosis.

Avoid stopping prescribed treatment solely because symptoms have improved for a few days. Plan reductions with the clinician and know what to do if symptoms return. The aim is enough treatment to control the disease, with continuing attention to both benefit and harm. [6]

Sources and further reading

  1. NIAMS. Reactive Arthritis: Diagnosis, Treatment, and Steps to Take.
  2. Clegg DO et al. Comparison of sulfasalazine and placebo in the treatment of reactive arthritis (Reiter’s syndrome). Arthritis Rheum. 1996;39:2021–2027.
  3. Egsmose C et al. Limited effect of sulphasalazine treatment in reactive arthritis. A randomised double blind placebo controlled trial. Ann Rheum Dis. 1997;56:32–36.
  4. Rüegg L et al. EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation: 2024 update. Ann Rheum Dis. 2025;84:910–926.
  5. Mruthyunjaya P et al. Short-Term Effectiveness of Sulfasalazine and Tofacitinib in NSAID-Refractory Reactive Arthritis: An Observational Study. Int J Rheum Dis. 2025;28:e70370.
  6. NIAMS. Reactive Arthritis: overview, diagnosis, treatment and steps to take.
  7. American College of Rheumatology. Reactive Arthritis. Patient information, updated 2025.
  8. Meyer A et al. Anti-TNF therapy in ten patients with refractory reactive arthritis. Arthritis Rheum. 2011;63:1274–1280.
  9. Thorsteinsson B et al. TNF inhibitors in reactive arthritis: Icelandic nationwide experience. J Rheumatol. 2020;47:1575–1581.

Educational information. Your treatment plan depends on your examination, test results and medical history.

Share this page

FacebookLinkedInXWhatsAppTelegram

Topics: Reactive arthritisSpondyloarthritis